Mepolizumab improves small airway function in severe eosinophilic asthma

Claude S. Farah, Tanya Badal, Nicola Reed, Peter G. Rogers, Gregory G. King, Cindy Thamrin, Matthew J. Peters, Leigh M. Seccombe

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background and objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown. Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab. Methods: Prospective cohort of 20 adults (12 male) with SEA commencing monthly mepolizumab. Measurements at baseline, Week 4 and Week 26 included the Asthma Control Questionnaire (ACQ-5), spirometry, fraction of exhaled nitric oxide (FeNO) and multiple breath nitrogen washout to measure global (Lung Clearance Index, [LCI]) and regional ventilation inhomogeneity in acinar (Sacin) and conducting (Scond) airways. Other asthma therapy remained unchanged between baseline and Week 4. Treatment related changes were assessed using RM-ANOVA and paired t-tests. Relationships between changes in lung function and symptoms were assessed by Pearson's correlation. Results: At Week 4, ACQ-5, spirometry, LCI and Sacin improved significantly (p < 0.04) and all were sustained at Week 26. The change in ACQ-5 correlated with the change in Sacin (r = 0.48, p = 0.03) and FRC (r = 0.46, p = 0.04), but not spirometry. Conclusion: Improved symptom control improved rapidly after commencing mepolizumab in patients with SEA. The early improvement in small airway function was associated with asthma control and may be a significant contributor to the therapeutic response.

LanguageEnglish
Pages49-53
Number of pages5
JournalRespiratory Medicine
Volume148
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Asthma
Spirometry
Lung
Ventilation
Therapeutics
mepolizumab
Analysis of Variance
Nitric Oxide
Nitrogen

Keywords

  • Asthma
  • Interleukin-5
  • Nitrogen washout test
  • Small airways
  • Ventilation heterogeneity

Cite this

Farah, C. S., Badal, T., Reed, N., Rogers, P. G., King, G. G., Thamrin, C., ... Seccombe, L. M. (2019). Mepolizumab improves small airway function in severe eosinophilic asthma. Respiratory Medicine, 148, 49-53. https://doi.org/10.1016/j.rmed.2019.01.016
Farah, Claude S. ; Badal, Tanya ; Reed, Nicola ; Rogers, Peter G. ; King, Gregory G. ; Thamrin, Cindy ; Peters, Matthew J. ; Seccombe, Leigh M. / Mepolizumab improves small airway function in severe eosinophilic asthma. In: Respiratory Medicine. 2019 ; Vol. 148. pp. 49-53.
@article{26b243c31bc247818efddad83ce3a49a,
title = "Mepolizumab improves small airway function in severe eosinophilic asthma",
abstract = "Background and objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown. Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab. Methods: Prospective cohort of 20 adults (12 male) with SEA commencing monthly mepolizumab. Measurements at baseline, Week 4 and Week 26 included the Asthma Control Questionnaire (ACQ-5), spirometry, fraction of exhaled nitric oxide (FeNO) and multiple breath nitrogen washout to measure global (Lung Clearance Index, [LCI]) and regional ventilation inhomogeneity in acinar (Sacin) and conducting (Scond) airways. Other asthma therapy remained unchanged between baseline and Week 4. Treatment related changes were assessed using RM-ANOVA and paired t-tests. Relationships between changes in lung function and symptoms were assessed by Pearson's correlation. Results: At Week 4, ACQ-5, spirometry, LCI and Sacin improved significantly (p < 0.04) and all were sustained at Week 26. The change in ACQ-5 correlated with the change in Sacin (r = 0.48, p = 0.03) and FRC (r = 0.46, p = 0.04), but not spirometry. Conclusion: Improved symptom control improved rapidly after commencing mepolizumab in patients with SEA. The early improvement in small airway function was associated with asthma control and may be a significant contributor to the therapeutic response.",
keywords = "Asthma, Interleukin-5, Nitrogen washout test, Small airways, Ventilation heterogeneity",
author = "Farah, {Claude S.} and Tanya Badal and Nicola Reed and Rogers, {Peter G.} and King, {Gregory G.} and Cindy Thamrin and Peters, {Matthew J.} and Seccombe, {Leigh M.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.rmed.2019.01.016",
language = "English",
volume = "148",
pages = "49--53",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W. B. Saunders",

}

Mepolizumab improves small airway function in severe eosinophilic asthma. / Farah, Claude S.; Badal, Tanya; Reed, Nicola; Rogers, Peter G.; King, Gregory G.; Thamrin, Cindy; Peters, Matthew J.; Seccombe, Leigh M.

In: Respiratory Medicine, Vol. 148, 01.03.2019, p. 49-53.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Mepolizumab improves small airway function in severe eosinophilic asthma

AU - Farah, Claude S.

AU - Badal, Tanya

AU - Reed, Nicola

AU - Rogers, Peter G.

AU - King, Gregory G.

AU - Thamrin, Cindy

AU - Peters, Matthew J.

AU - Seccombe, Leigh M.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background and objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown. Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab. Methods: Prospective cohort of 20 adults (12 male) with SEA commencing monthly mepolizumab. Measurements at baseline, Week 4 and Week 26 included the Asthma Control Questionnaire (ACQ-5), spirometry, fraction of exhaled nitric oxide (FeNO) and multiple breath nitrogen washout to measure global (Lung Clearance Index, [LCI]) and regional ventilation inhomogeneity in acinar (Sacin) and conducting (Scond) airways. Other asthma therapy remained unchanged between baseline and Week 4. Treatment related changes were assessed using RM-ANOVA and paired t-tests. Relationships between changes in lung function and symptoms were assessed by Pearson's correlation. Results: At Week 4, ACQ-5, spirometry, LCI and Sacin improved significantly (p < 0.04) and all were sustained at Week 26. The change in ACQ-5 correlated with the change in Sacin (r = 0.48, p = 0.03) and FRC (r = 0.46, p = 0.04), but not spirometry. Conclusion: Improved symptom control improved rapidly after commencing mepolizumab in patients with SEA. The early improvement in small airway function was associated with asthma control and may be a significant contributor to the therapeutic response.

AB - Background and objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown. Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab. Methods: Prospective cohort of 20 adults (12 male) with SEA commencing monthly mepolizumab. Measurements at baseline, Week 4 and Week 26 included the Asthma Control Questionnaire (ACQ-5), spirometry, fraction of exhaled nitric oxide (FeNO) and multiple breath nitrogen washout to measure global (Lung Clearance Index, [LCI]) and regional ventilation inhomogeneity in acinar (Sacin) and conducting (Scond) airways. Other asthma therapy remained unchanged between baseline and Week 4. Treatment related changes were assessed using RM-ANOVA and paired t-tests. Relationships between changes in lung function and symptoms were assessed by Pearson's correlation. Results: At Week 4, ACQ-5, spirometry, LCI and Sacin improved significantly (p < 0.04) and all were sustained at Week 26. The change in ACQ-5 correlated with the change in Sacin (r = 0.48, p = 0.03) and FRC (r = 0.46, p = 0.04), but not spirometry. Conclusion: Improved symptom control improved rapidly after commencing mepolizumab in patients with SEA. The early improvement in small airway function was associated with asthma control and may be a significant contributor to the therapeutic response.

KW - Asthma

KW - Interleukin-5

KW - Nitrogen washout test

KW - Small airways

KW - Ventilation heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85061096292&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2019.01.016

DO - 10.1016/j.rmed.2019.01.016

M3 - Article

VL - 148

SP - 49

EP - 53

JO - Respiratory Medicine

T2 - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -